Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Rocket Companies Q1 2026 Earnings Call - AI and Integration Drive Record Profitability and Market Share Gains
Rocket Companies delivered its most profitable quarter in four years, with adjusted revenue surpassing guidance and adjusted EBITDA margins expanding to 26%. The company is leveraging its integrated e...
- Adjusted revenue reached $2.82 billion, beating the high end of guidance, driven by strong performance across origination, servicing, and Redfin channels.
- Adjusted EBITDA surged to $738 million, with margins expanding to 26% from 23% in the prior quarter, marking the most profitable quarter in four years.
- Net rate lock volume grew 19% quarter-over-quarter to $49 billion, with market share gains in both purchase and refinance segments.
- +9 more takeaways
OmniAb Q1 2026 Earnings Call - Milestone-Driven Revenue Surge and xPloration Momentum Signal Accelerating Partner Validation
OmniAb reported a sharp revenue jump in Q1 2026, driven by partner milestones that pushed total revenue to $14.4 million from $4.2 million year-over-year. The company raised its full-year revenue guid...
- Q1 2026 revenue surged to $14.4 million, up from $4.2 million in Q1 2025, primarily due to higher milestone payments from advancing partner programs.
- Full-year 2026 revenue guidance was raised to $28 million–$33 million, up from prior expectations, driven by an unexpected milestone achievement in Q1.
- GAAP operating expenses decreased to $22.3 million from $23 million, though a $2.9 million non-cash write-off on legacy assets obscured underlying cost efficiencies.
- +7 more takeaways
Senseonics Q1 2026 Earnings Call - Revenue Surges 85% as Commercial Integration Drives Margin Expansion
Senseonics delivered a robust Q1 2026, reporting $11.7 million in revenue, an 85% year-over-year increase, and a 58% gross margin. The company successfully integrated its U.S. commercial organization ...
- Q1 2026 revenue reached $11.7 million, an 85% year-over-year increase, driven by strong Eversense 365 adoption and a favorable shift toward higher-margin bundled reimbursement channels.
- Gross margin expanded to 58%, reflecting higher average selling prices, increased manufacturing volumes, and the structural benefit of eliminating the Ascensia revenue share.
- Senseonics raised its full-year 2026 global net revenue guidance to $60-$64 million, representing 70-82% year-over-year growth, up from the previous range of $58-$62 million.
- +12 more takeaways
Full House Resorts Q1 2026 Earnings Call - Construction Financing Nears Completion as Marketing Shifts Drive Colorado Revenue Growth
Full House Resorts reported a solid first quarter with revenues of $74.4 million and adjusted EBITDA rising 15% to $13.2 million, driven by strong performance at American Place and cost discipline acr...
- Revenues of $74.4 million in Q1 2026, down slightly from $75.1 million in Q1 2025, but up 0.9% on an apples-to-apples basis after excluding Stockman’s revenue.
- Adjusted EBITDA rose 15% to $13.2 million, up from $11.5 million in Q1 2025, reflecting strong profitability improvements.
- American Place temporary casino drove 7% revenue growth to $31.8 million, with adjusted property EBITDA up 8% to $8.3 million, despite a 1.2 percentage point decline in table games hold.
- +7 more takeaways
BILL Q3 2026 Earnings Call - AI-Native Pivot and 30% Workforce Reduction Signal a New Era
BILL delivered a quarter of decisive structural change. Core revenue grew 16% to $371 million, while non-GAAP operating margin expanded sharply to 20% and the company achieved GAAP profitability. Mana...
- Core revenue grew 16% year-over-year to $371 million, extending a strong trajectory of durable growth.
- Non-GAAP operating margin reached 20%, expanding 475 basis points year-over-year and surpassing guidance.
- BILL achieved GAAP profitability for the first time, signaling a shift toward sustained earnings generation.
- +12 more takeaways
Arcturus Therapeutics Q1 2026 Earnings Call - Inhaled mRNA CF Program Achieves Unprecedented Tolerability Beyond One Month
Arcturus Therapeutics delivered a quarter defined by clinical momentum and strategic refocusing. The company initiated its 12-week open-label Phase II study for ARCT-032, its inhaled mRNA candidate fo...
- Arcturus initiated a 12-week open-label Phase II study for ARCT-032 in Class 1 cystic fibrosis patients, a critical step for an inhaled mRNA therapy.
- Management highlighted that continuous dosing beyond one month has never been successfully tolerated with inhaled mRNA therapeutics, a key differentiator for their platform.
- The company is evaluating lung function metrics including percent predicted FEV1 and lung clearance index (LCI) to assess early clinical benefit.
- +7 more takeaways
Fox Factory Holding Corp Q1 2026 Earnings Call - Cost Cuts Offset Tariffs as Management Reaffirms 2026 Outlook
Fox Factory delivered Q1 revenue of $368.7 million, hitting the high end of guidance, while adjusted EBITDA of $35.7 million beat expectations. Management is reaffirming its full-year 2026 outlook, ex...
- Q1 revenue of $368.7 million hit the high end of guidance, while adjusted EBITDA of $35.7 million exceeded expectations.
- Management reaffirmed full-year 2026 guidance, expecting net sales between $1.328 billion and $1.416 billion and adjusted EBITDA between $174 million and $203 million.
- The company is executing on a $50 million cost-saving initiative, with $10 million in carryover and $40 million in new phase 2 actions.
- +7 more takeaways
Profound Medical Q1 2026 Earnings Call - First Formal Guidance Set as TULSA Platform Gains Reimbursement Traction
Profound Medical delivered a decisive Q1 2026 quarter, flipping revenue growth into sharper losses while locking in its first formal full-year guidance of CAD 25 million. The company’s TULSA platform ...
- Revenue surged 104% year-over-year to CAD 5.3 million, driven by a mix of CAD 2.9 million in capital equipment sales and CAD 2.5 million in recurring revenue.
- Net loss narrowed sharply to CAD 7 million from CAD 10.7 million a year ago, with operating expenses falling 9% to CAD 11.8 million as the company scales.
- Gross margin expanded to 72% from 71% in Q1 2025, primarily due to a favorable product mix favoring higher-margin capital equipment sales.
- +7 more takeaways
Forward Air Q1 2026 Earnings Call - Strategic Pivot Amid Customer Diversification and Intermodal Sale
Forward Air reported a solid Q1 2026 with operating income of $20M and consolidated EBITDA of $70M, demonstrating margin stability across its core Expedited and Omni Logistics segments. However, the c...
- Operating income improved to $20 million in Q1 2026, up from $5 million in Q1 2025, while consolidated EBITDA was $70 million, slightly down from $73 million a year ago.
- Expedited Freight segment EBITDA rose to $28 million from $26 million year-over-year, maintaining a stable 10.4% margin.
- Omni Logistics segment EBITDA remained flat at $25 million, with margins improving to 7.9% from 8.3% due to a mix shift toward higher-margin contract logistics.
- +10 more takeaways
Sensus Healthcare Q1 2026 Earnings Call - New CPT Codes Drive Recurring Revenue Pivot
Sensus Healthcare reported a sharp revenue decline to $3.4 million in Q1 2026, a direct consequence of shedding its reliance on a single large customer that accounted for $5.6 million in the prior yea...
- Revenue fell to $3.4 million from $8.3 million year-over-year, primarily due to zero sales to a historically large customer that contributed $5.6 million in Q1 2025.
- Excluding the large customer, underlying revenue grew to $3.4 million from $2.7 million, signaling organic demand across a more diversified base.
- Dedicated CPT codes for superficial radiotherapy, effective January 1, 2026, have eliminated reimbursement uncertainty and driven a 300% increase in per-fraction payment rates.
- +7 more takeaways